Genmab Announces Rinatabart Sesutecan (Rina-S®) Demonstrates Statistically Significant Improvement in Progression-Free Survival and Overall Survival in Patients with Platinum-Resistant Ovarian Cancer

What happened: Genmab (Nasdaq: GMAB) reported positive topline results from the Phase 3 RAINFOL-02 trial of rinatabart sesutecan (Rina-S) in platinum-resistant ovarian cancer, meeting its primary PFS endpoint and key secondary OS endpoint versus investigator's choice Why it matters: Genmab said the results strengthen its confidence in Rina-S and advance its ambition to become a leader in gynecologic oncology. The study's lead investigator said the data set a new benchmark and could change clinical practice if approved. Genmab plans to engage regulatory authorities worldwide.

Genmab (Nasdaq: GMAB) reported positive topline results from the Phase 3 RAINFOL-02 trial of rinatabart sesutecan (Rina-S) in platinum-resistant ovarian cancer, meeting its primary PFS endpoint and key secondary OS endpoint versus investigator's choice

Genmab said the results strengthen its confidence in Rina-S and advance its ambition to become a leader in gynecologic oncology. The study's lead investigator said the data set a new benchmark and could change clinical practice if approved. Genmab plans to engage regulatory authorities worldwide.